MAIWEIJIAN Becomes First Biosimilar of Denosumab

MAIWEIJIAN Becomes First Biosimilar of Denosumab

By, Admin 10 April 2024

MAIWEIJIAN becomes first approved biosimilar of Denosumab (120mg) in China

Overview

Biopharmaceutical company Mabwell has announced that Denosumab Injection (trade name- MAIWEIJIAN) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing authorisation approval by National Medical Products Administration (NMPA). MAIWEIJIAN is the first denosumab biosimilar (120mg) approved for marketing in China.

MAIWEIJIAN

MAIWEIJIAN is a fully human recombinant anti-RANKL monoclonal antibody injection, approved to treat giant cell tumour of the bone that is unresectable or where surgical resection may lead to severe functional impairment, including in adults and adolescents with mature skeletal development.

Denosumab

  • Denosumab, due to its demonstrated good therapeutic effects, has been recommended by multiple expert consensuses or treatment guidelines. 
  • Doctors and patients have a high level of recognition for denosumab. 

Market Presence

  • Apart from MAIWEIJIAN, no other biosimilar drugs are currently on the market in China. 
  • In 2022, its sales amounted to 427 million yuan in China.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!